In the ongoing battle against drug shortages, the pharmaceutical industry could soon face additional constraints. A new provision proposed by the French Social Security Financing Bill for 2024 carries considerable implications. It could require companies marketing a mature therapeutic drug of major interest who wish to suspend or stop selling it, to ensure, in certain circumstances, the maintenance of its product’s supply on the French market by obliging them to find a buyer, according to global law firm Hogan Lovells.
This initiative aims to mitigate risks related to the supply of essential pharmaceuticals, ensuring that key therapeutic drugs remain accessible to those who depend on them. It reflects a growing global concern over potential interruptions in medical supplies, further fuelled by unpredictable disruptions during the COVID-19 pandemic.
Pharmaceutical businesses managing mature therapeutic drugs will need to re-evaluate their strategies and consider potential transactional considerations alongside this new legislative development. This added responsibility of finding a suitable buyer and securing supply continuity before ceasing drug distribution elevates the challenges already faced by the industry.
It is anticipated that the proposition will invite a wide range of responses, both within France and globally, underlining the continued scrutiny directed at the pharmaceutical industry and the ongoing demand for pharmaceutical risk mitigation. However, it is a compelling reminder of the importance of safeguarding access to essential health care and the industry’s role within it.